专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20120094902A1 Fast-acting insulin formulation 审中-公开
标题翻译：速效胰岛素制剂
公开(公告)号：US20120094902A1
公开(公告)日：2012-04-19
申请号：US13287793
申请日：2011-11-02
申请人： Olivier Soula , Rémi Soula , Gerard Soula
发明人： Olivier Soula , Rémi Soula , Gerard Soula
IPC分类号： A61K38/28 , C07K1/107 , A61P3/10 , C07K14/62
CPC分类号： A61K38/28 , A61K9/0019 , A61K47/61
摘要： A complex between an insulin and a polysaccharide comprising carboxyl functional groups is described, the polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, the phenylalanine derivative being chosen from phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and the insulin being either a human insulin or an insulin analog. A pharmaceutical composition including at least one complex, especially in the form of an injectable solution, is also described.
摘要翻译：描述了胰岛素和包含羧基官能团的多糖之间的复合物，所述多糖选自用至少一种苯丙氨酸衍生物官能化的多糖，注意到Phe，苯丙氨酸衍生物选自苯丙氨酸及其碱金属阳离子盐，苯丙氨醇，苯丙氨酰胺和乙基苄胺或苯丙氨酸酯，胰岛素是人胰岛素或胰岛素类似物。还描述了包含至少一种复合物，特别是可注射溶液形式的药物组合物。

42. 发明申请

US20110159068A1 Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support 审中-公开
标题翻译：包含生长因子/两亲性聚合物复合物，可溶性阳离子盐和有机载体的成骨组合物
公开(公告)号：US20110159068A1
公开(公告)日：2011-06-30
申请号：US13064092
申请日：2011-03-04
申请人： Remi Soula , Olivier Soula , Gerard Soula
发明人： Remi Soula , Olivier Soula , Gerard Soula
IPC分类号： A61K38/18 , A61F2/00 , A61P43/00 , A61P19/00 , B29C35/16
CPC分类号： A61K38/1866 , A61K33/06 , A61K33/26 , A61K33/30 , A61K38/1825 , A61K38/1858 , A61K38/1875 , A61L27/20 , A61L27/227 , A61L27/54 , A61L2300/414 , C08B37/0021 , C08B37/0072 , C08B37/0084 , A61K2300/00
摘要： An open implant constituted of an osteogenic composition comprising at least one osteogenic growth factor/amphiphilic anionic polysaccharide complex, one soluble salt of a cation at least divalent, and one organic support, said organic support comprising no demineralized bone matrix. In one embodiment, said implant is in the form of a lyophilizate. It also relates to the method for the preparation thereof.
摘要翻译：由包含至少一种成骨生长因子/两亲性阴离子多糖复合物，至少二价阳离子的一种可溶性盐和一种有机载体的成骨组合物构成的开放式植入物，所述有机载体不包含软化骨基质。在一个实施方案中，所述植入物是冻干物的形式。它还涉及其制备方法。

43. 发明申请

US20110014189A1 Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents 审中-公开
标题翻译：稳定的药物组合物，其包含至少一种单克隆抗体和至少一种包含疏水取代基的两亲性多糖
公开(公告)号：US20110014189A1
公开(公告)日：2011-01-20
申请号：US12654552
申请日：2009-12-23
申请人： Olivier Soula , Gerard Soula , Martin Gaudier , Remi Soula
发明人： Olivier Soula , Gerard Soula , Martin Gaudier , Remi Soula
IPC分类号： A61K39/395 , A61P17/00 , A61P35/00 , A61P11/00 , A61P29/00 , A61P37/00 , A61P9/00 , A61P25/00 , A61P1/00 , A61P3/00 , A61P5/00
CPC分类号： A61K39/39591 , A61K47/26 , A61K47/36 , C07K16/22 , Y02A50/394
摘要： A stable pharmaceutical composition with at least one monoclonal antibody and at least one amphiphilic polysaccharide chosen from the group of amphiphilic polysaccharides comprising carboxylate functional groups partly substituted with at least one hydrophobic substituent is disclosed.
摘要翻译：公开了具有至少一种单克隆抗体和至少一种两亲性多糖的稳定药物组合物，其选自包含部分被至少一个疏水性取代基取代的羧酸官能团的两亲性多糖组。

44. 发明申请

US20100266701A1 ANTI-MISUSE MICROPARTICULATE ORAL DRUG FORM 审中-公开
标题翻译：抗微生物口服药物形式
公开(公告)号：US20100266701A1
公开(公告)日：2010-10-21
申请号：US12560044
申请日：2009-09-15
申请人： Florence Guimberteau , Remi Meyrueix , Gerard Soula
发明人： Florence Guimberteau , Remi Meyrueix , Gerard Soula
IPC分类号： A61K9/14 , A61K31/52 , A61K31/155
CPC分类号： A61K9/5047 , A61K9/5078 , A61K31/196 , A61K31/522
摘要： The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. Another aim of the invention is to provide novel analgesic drugs which can be used to: prevent the misuse of, and addiction to certain analgesics and/or to control plasma concentration variability and/or to facilitate oral; administration; and/or to combine analgesics with one another and/or with one or more active ingredients in the same oral form. More specifically, the invention relates to a solid oral drug form comprising anti-misuse means and at least one active ingredient, which is characterized in that: at least part of the active ingredient is contained in microparticles; and the anti-misuse means comprise anti-crushing means (a) which enable the microparticles of the active ingredient to resist crushing, such as to prevent the misuse thereof. According to the invention, the drug form can also comprise means (b) for preventing the misuse of the active ingredient following a possible liquid extraction process.
摘要翻译：本发明涉及具有防止滥用其中所含的活性药物成分（API）的组合物的固体微粒口服剂型。本发明的目的是防止不适当地使用固体口服药物以用于由适当的公共卫生当局正式批准的治疗用途以外的任何用途。本发明的另一个目的是提供新的止痛药，其可用于：防止某些止痛剂的滥用和成瘾和/或控制血浆浓度变异性和/或促进口服; 行政; 和/或将镇痛药彼此和/或以相同口服形式的一种或多种活性成分组合。更具体地，本发明涉及包含抗滥用手段和至少一种活性成分的固体口服药物形式，其特征在于：至少部分活性成分包含在微粒中; 并且防误用手段包括能够使活性成分的微粒抵抗破碎的抗破碎装置（a），以防止其误用。根据本发明，药物形式还可以包括用于防止在可能的液体提取过程后滥用活性成分的装置（b）。

45. 发明申请

US20100166867A1 Novel administration form of osteogenic protein complexes 失效
标题翻译：成骨蛋白复合物的新型管理形式
公开(公告)号：US20100166867A1
公开(公告)日：2010-07-01
申请号：US12591442
申请日：2009-11-19
申请人： Olivier SOULA , Remi SOULA , Gerard SOULA
发明人： Olivier SOULA , Remi SOULA , Gerard SOULA
IPC分类号： A61K38/18 , A61K9/14 , A61P19/00
CPC分类号： A61K31/721 , A61K9/0019 , A61K9/0024 , A61K9/143 , A61K9/146 , A61K9/19 , A61K33/06 , A61K33/42 , A61K38/1858 , A61K38/1875 , A61K47/02 , A61K47/36 , A61L27/227 , A61L27/26 , A61L27/54 , A61L2300/252 , A61L2300/414 , A61L2300/45 , A61L2300/802 , C08B37/0021 , A61K2300/00 , C08L89/00
摘要： The invention relates to osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, said coprecipitate being in divided form. The invention also relates to kits for performing the invention.The invention also relates to the process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide.The invention also relates to the formulations, pharmaceutical products and medical devices comprising said coprecipitate.
摘要翻译：本发明涉及由含有至少一种不溶性钙盐和至少一种成骨蛋白质和多糖之间的复合物的共沉淀物组成的成骨组合物，所述共沉淀物是分开形式的。本发明还涉及用于实施本发明的试剂盒。本发明还涉及分离形式的共沉淀物的制备方法，其含有至少一种不溶性钙盐和至少一种成骨蛋白质和多糖之间的复合物。本发明还涉及包含所述共沉淀物的制剂，药物产品和医疗装置。

46. 发明申请

US20100009911A1 Osteogenic synergic composition 审中-公开
标题翻译：成骨协同组合物
公开(公告)号：US20100009911A1
公开(公告)日：2010-01-14
申请号：US12457095
申请日：2009-06-01
申请人： Gerard Soula
发明人： Gerard Soula
IPC分类号： A61K38/18 , A61P19/08
CPC分类号： A61L27/54 , A61L27/26 , A61L2300/414 , A61L2300/45 , A61L2430/02 , C08L89/00
摘要： The invention relates to an osteogenic synergic composition comprising at least one osteogenic growth factor, and at least one growth factor having a chemoattractant and angiogenic capacity. It also relates to the method for the preparation thereof and to the use thereof for the preparation and production of pharmaceutical products for use in bone reconstruction and regeneration, in the form of topical compositions, for example implants, pastes or gels.
摘要翻译：本发明涉及包含至少一种成骨生长因子和至少一种具有化学引诱物和血管发生能力的生长因子的成骨协同组合物。它还涉及其制备方法及其用于制备和生产用于骨重建和再生的药物产品的用途，其为局部组合物，例如植入物，糊剂或凝胶。

47. 发明申请

US20070202049A1 Oral dosage form comprising an antimisuse system 审中-公开
标题翻译：包含抗炎系统的口服剂型
公开(公告)号：US20070202049A1
公开(公告)日：2007-08-30
申请号：US11439247
申请日：2006-05-24
申请人： Florence Guimberteau , Frederic Dargelas , Gerard Soula , Remi Soula
发明人： Florence Guimberteau , Frederic Dargelas , Gerard Soula , Remi Soula
IPC分类号： A61K9/44
CPC分类号： A61K9/5047 , A61K9/4825 , A61K9/5078 , A61K9/5084 , A61K33/06 , A61K33/26 , A61K33/30 , A61K45/06 , A61K2300/00
摘要： An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.
摘要翻译：含有一种或多种具有止痛特性的活性成分的口服固体剂型，所述剂型的组成使得其通过液体提取其中包含的活性成分来防止所述剂型的滥用，其使用常用的溶剂。所述口服固体剂型含有至少一种至少一种止痛活性成分的盐，以及包含至少一种猝灭剂的抗滥用系统，所述猝灭剂适合于诱导所述止痛活性成分盐在所述止痛活性成分在所述口服固体剂型的溶液中，盐不适当地提取，特别是药物滥用者。

48. 发明申请

US20070190162A1 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same 审中-公开
标题翻译：用于递送活性成分的亚微粒子的胶体悬浮液及其制备方法
公开(公告)号：US20070190162A1
公开(公告)日：2007-08-16
申请号：US11583941
申请日：2006-10-20
申请人： Sylvain Caillol , Remi Meyruiex , Nathan Bryson , Alain Soum , Gerard Soula , Anne-Francoise Mingotaud
发明人： Sylvain Caillol , Remi Meyruiex , Nathan Bryson , Alain Soum , Gerard Soula , Anne-Francoise Mingotaud
IPC分类号： A61K9/14
CPC分类号： A61K8/88 , A61K8/0241 , A61K9/5153 , A61K9/5192 , A61K2800/413 , A61K2800/56 , A61Q19/00 , B82Y5/00 , C08G81/00 , C08J3/14 , C08J2377/12
摘要： The present invention is directed to a suspension of particles for delivering active principles, in particular proteins. Said particles are based on a diblock copolymer consisting of a neutral hydrophobic alpha hydroxy carboxylic acid polymer block and a hydrophilic linear polyaminoacid block with peptide alpha chaining, at least partly ionized. Said alpha hydroxy carboxylic acid polymer/linear polyaminoacid delivery particles spontaneously obtainable in the absence of surfactant can be stable. Said delivery particles are capable of being associated undissolved in colloidal suspension with at least an active principle and of delayed or prolonged release thereof. The invention is also directed to a powdery solid from which are derived the delivery particles and the preparation of said solid and said delivery particle suspension.
摘要翻译：本发明涉及用于递送活性成分的颗粒的悬浮液，特别是蛋白质。所述颗粒基于由中性疏水性α羟基羧酸聚合物嵌段和具有至少部分电离的肽α链的亲水性线性聚氨基酸嵌段组成的二嵌段共聚物。在不存在表面活性剂的情况下自发获得的所述α羟基羧酸聚合物/线性聚氨基酸输送颗粒可以是稳定的。所述递送颗粒能够以至少一种活性成分和延迟或延长释放的胶体悬浮液的形式相互不溶解。本发明还涉及粉末状固体，其衍生自所述输送颗粒以及所述固体和所述输送颗粒悬浮液的制备。

49. 发明申请

US20050037077A1 Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles 审中-公开
标题翻译：用于延迟和控制释放药物活性成分的Galenic微粒口服制剂
公开(公告)号：US20050037077A1
公开(公告)日：2005-02-17
申请号：US10492129
申请日：2002-10-09
申请人： Valerie Legrand , Catherine Castan , Remi Meyrueix , Gerard Soula
发明人： Valerie Legrand , Catherine Castan , Remi Meyrueix , Gerard Soula
IPC分类号： A61K9/14 , A61K9/22 , A61K9/26 , A61K9/48 , A61K9/50 , A61K9/52 , A61K31/155 , A61K31/522 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61P3/10 , A61P7/02 , A61P15/18 , A61P25/00 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12
CPC分类号： A61K9/5078
摘要： The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system consists of microcapsules (200 to 600 μm) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5. These microcapsules have a dissolution behavior in vitro such that, at a constant pH of 1.4, a latency phase of between 1 and 5 hours is observed, followed by a release of the AP, and such that the change from pH 1.4 to pH 6.8 results in a release of the AP without a latency period in vitro.
摘要翻译：本发明涉及一种用于延迟和控制释放活性成分（AP）的微粒体系，其活性成分在体内的吸收窗口基本上限于胃肠道的上部，该系统用于口服给药。本发明的目的是提供一种确保通过“时间依赖”和“依赖于pH”释放的双重机制确定地释放AP的系统。为了实现该目的，本发明提出了一种多微囊口服盖仑型，其设计以保证治疗功效，并且其中AP的释放由双时间触发机制（“触发时间”和“pH- 触发“。该系统由包含涂覆有包含亲水性聚合物A（EudragitL）和疏水性化合物B（植物蜡，熔点）的膜（最大40重量％））的AP芯组成的微胶囊（200至600μm） = 40-90℃），B / A在0.2和1.5之间。这些微胶囊在体外具有溶解行为，使得在1.4的恒定pH下，观察到1至5小时的潜伏期，随后释放AP，并且使得从pH1.4变为pH6.8的结果在AP的释放中没有潜伏期在体外。

50. 发明授权

US5214176A Organosilicon compounds 失效
标题翻译：有机硅化合物
公开(公告)号：US5214176A
公开(公告)日：1993-05-25
申请号：US340778
申请日：1989-04-20
申请人： Gerard Soula , Gerard Mignani
发明人： Gerard Soula , Gerard Mignani
IPC分类号： G02F1/35 , C07F7/08 , C07F7/10 , C07F7/12 , C07F9/40 , G02F1/355 , G02F1/361
CPC分类号： G02F1/3619 , C07F7/0821
摘要： Novel organosilicon compounds having a second order hyperpolarizability coefficient .beta. greater than zero, well suited for use in the field of nonlinear optics, e.g., in telecommunication devices, have the general formula: ##STR1## which n is an integer ranging from 1 to 20; R.sub.1 is an electron donating group; R.sub.2 is an electron accepting group; R.sub.3 is an alkyl radical having from 1 to 8 carbon atoms, a hydrogen atom, an aryl radical, or an R.sub.1 or R.sub.2 radical; and R.sub.4 is an alkyl radical having from 1 to 8 carbon atoms, a hydrogen atom, an aryl radical, or an R.sub.1 radical when R.sub.3 is not an R.sub.2 radical or an R.sub.2 radical when R.sub.3 is not an R.sub.1 radical.
摘要翻译：具有二阶超极化率系数β大于零的新型有机硅化合物，非常适合用于非线性光学领域，例如在电信设备中，具有以下通式：其中n是1至20的整数; R1是给电子基团; R2是电子接受基团; R3是具有1至8个碳原子的烷基，氢原子，芳基或R1或R2基团; 当R 3不是R 1基团时，当R 3不是R 2基团或R 2基团时，R 4是具有1至8个碳原子的烷基，氢原子，芳基或R 1基团。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式